EREG and neoplasm: It is important to note, however, that AhR antagonism may not benefit all type of cancers as, as noted in the sections above, in a subset of diseases AhR has been shown to act as a tumor suppressor (i.e. ER+ breast cancer, androgen-sensitive prostate cancer, non-MYCN-amplified neuroblastoma, see Figure 3).